Sciatica Therapy Tablet, Orally Disintegrating
NDC Package 17312-021-14
Package Information
Sciatica Therapy (arnica montana - citrullus colocynthis fruit pulp - pseudognaphalium obtusifolium - hypericum perforatum - potassium iodide - magnesium phosphate, dibasic trihydrate - toxicodendron pubescens leaf -) tablets is uses: According to homeopathic indications these ingredients provide temporary relief from symptoms of Sciatica such as: • back aches • nerve discomfort • leg numbness • tingling legs • shooting discomfort • stiffness • tearing pain after serious causes have been ruled out by a physician. This formulation utilizes a tablet, orally disintegrating delivery system. Marketed by Trp Company, this product is identified by NDC 17312-021.
Identification & Billing
Clinical Specifications
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
Regulatory & Marketing
Hierarchy Structure
- 17312 - Trp Company
- 17312-021 - Sciatica Therapy
- 17312-021-14 - 1 BOTTLE in 1 PACKAGE / 70 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE
- 17312-021 - Sciatica Therapy
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 17312-021-14 identifies a specific commercial package of 1 bottle in 1 package / 70 tablet, orally disintegrating in 1 bottle of Sciatica Therapy, a human over the counter drug labeled by Trp Company. This tablet, orally disintegrating is formulated for oral use and contains arnica montana; citrullus colocynthis fruit pulp; hypericum perforatum; magnesium phosphate, dibasic trihydrate; potassium iodide; pseudognaphalium obtusifolium; toxicodendron pubescens leaf as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Trp Company on December 01, 2011. The current certification is valid through December 31, 2026.
How is this Trp Company product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 17312002114. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.